What is it that the PBM industry doesn’t want you to know?” asked the CEO of the Florida Pharmacy Association.

Ed Kaplan, the national health practice leader at Segal, also has concerns about "any willing provider" strategies.

Another pressing concern for participants was the rise in drug costs, with 54% expecting at least half of U.S. states to establish drug-affordability boards. Additionally, 97% foresee a 25% surge in ...

Policymakers at the federal and state level have considered a number of reforms, many of which have bipartisan support, to ...

The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...

The "FDA Inspection" training has been added to ResearchAndMarkets.com's offering. This seminar provides the fundamentals and the ground rules on how to prepare for and survive an FDA inspection no ...

Biocatalysis in drug manufacturing market, valued at USD 1,738.3 M in 2035, is set to grow at a 7.8% CAGR through 2035, driven by enzyme-based drug demand.

Novo Nordisk launches NovoCare Pharmacy, offering uninsured and cash-paying patients Wegovy for $499 per month. The service ...

Massachusetts Governor Maura Healy signed into law “An Act Relative To Pharmaceutical Access, Costs And Transparency.” The Act will ...

Honolulu (CN) — The state of Hawaii pressed a federal judge Friday to send its lawsuit against major pharmacy benefit ... assists the Office of Personnel Management (OPM) in implementing the Federal ...

During a hearing on Capitol Hill, members of the House Energy and Commerce Committee probed pharmaceutical benefit managers’ (PBMs) business practices, which have drawn bipartisan accusations of ...